Abstract
The study was carried out on 25 Haemoglobin E trait and 25 controls between 20 to 64 years of age. In all the participants' full blood count analysis and Haemoglobin variant analysis were done. Participants were selected after excluding all factors which affect red cell indices such as iron deficiency, vitamin B12 and folate deficiency, pregnancy, liver disease, hypothyroidism, chronic alcohol consumption, Diabetes mellitus, Metformin treatment and recent blood transfusion. Comparative analysis of all haematological parameters done between two groups separately for males and females.
Highlights
HamoglobinE (HbE) is the second commonest structural haemoglobin variant after Haemoglobin S with a mutation in the β globin gene causing substitution of glutamic acid for lysine at position 26 of the β globin chain [1]
Even when mean corpuscular volume (MCV) and mean corpuscular haemoglobin (MCH) are normal, people should be screened to exclude haemoglobin E hetrozygosity, if red cell count or red cell distribution width (RDW) is higher than the reference range for the age
A screening tool using red cell parameters would be cost effective in hospital settings as well as for mass screening programmes
Summary
HamoglobinE (HbE) is the second commonest structural haemoglobin variant after Haemoglobin S with a mutation in the β globin gene causing substitution of glutamic acid for lysine at position 26 of the β globin chain [1]. The β chain of HbE (βE) is synthesized at a reduced rate compared with that of normal adult Haemoglobin (Hb A) This is because the mutation creates an alternate splicing site within an exon. This results in a reduced rate of synthesis of βE chain and of HbE, and heterozygotes, compound heteozygotes and homozygotes show some β thalassemic features. HamoglobinE (HbE) is the second commonest structural haemoglobin variant and results from mutation in the β globin gene causing substitution of glutamic acid for lysine at position 26 of the β globin chain. When coinherited with β Thalassemia it becomes a major health burden
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Blood Research and Disorders
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
